AbbVie terminated a 2020 collaboration with Jacobio Pharmaceuticals centred on the development and commercialisation of SHP2 inhibitors
The Company announced today that AbbVie has delivered the termination notice of the parties’ license and collaboration agreement (the “Agreement”) for the global development and commercialization of SHP2 inhibitors licensed by Jacobio to AbbVie under the Agreement, as part of AbbVie’s overall strategic decisions on its portfolio priorities. Following the termination of the Agreement, Jacobio will regain the global rights previously granted to AbbVie to such SHP2 inhibitors, including decision-making authority over all development, commercialization, manufacturing, regulatory activities relating to SHP2 inhibitors globally. Jacobio will also have the rights to book sales for such SHP2 inhibitors on a global basis. Both parties will collaborate to orderly transition the responsibilities under the Agreement for a period no longer than 180 days. During the transitional period, AbbVie will continue to reimburse all cost under the pre-approved development plan.
Share:
More News
“FDA clearance of the IND for ORM-1153 is an important milestone for Orum, bringing another first-in-class DAC into the clinic and extending our approach into CD123-expressing hematologic malignancies,” said Olaf Christensen, M.D., Chief Medical Officer of Orum Therapeutics. “By combining cell-selective delivery with targeted protein degradation in a single molecule,
“We are excited to expand our clinical collaboration with Roche to evaluate a second KRAS combination with potential best-in-class MTA-cooperative PRMT5 inhibitor IDE892 for pancreatic cancer patients, where there remains a high unmet medical need. IDEAYA is advancing multiple rational combination strategies for the IDE892 program, including with MAT2A inhibitor
“These encouraging initial safety observations represent an important first step in the clinical evaluation of ZI-MA4-1 and our TCR-NK platform” said Namir Hassan, Chief Executive Officer of Zelluna. “The first patient received all three planned doses, and the independent committee’s recommendation enables us to continue recruitment at the first dose
“Receiving FTD is an important milestone for ERAS-0015 and reflects the urgent need for new therapies for patients with metastatic pancreatic cancer,” said Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder. “Together with the encouraging clinical activity and favorable tolerability observed to date, this FTD helps to position us